Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06757166

The Effect of NOn-invasive Respiratory Support on outcoMe and Its Risks in SARS-COV-2-related Hypoxemic Respiratory Failure

To determine whether early endotracheal intubation compared to late endotracheal intubation affects clinical outcome (duration of invasive mechanical ventilation, mortality).

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Erasmus Medical Centre

Rotterdam, South Holland, 3015GD, Netherlands

Location status: Recruiting

Location contact

Carmen A.T. Reep, MSc

CONTACT

[email protected]

+31628164764

About this study

Non-invasive respiratory support, especially HFNO is usually well-tolerated, especially in COVID-19 patients and can be applied for a prolonged period of time. However, there is a heated debate whether later/delayed endotracheal intubation (due to HFNO / NIV) increases the risk of lung injury, so-called patient self-inflicted lung-injury (P-SILI). The concept of P-SILI assumes that high forces applied to the lung resulting from strenuous breathing effort generated by the patient exacerbates lung-injury and is associated with adverse clinical outcome. It is therefore important to investigate if a longer period of non-invasive respiratory support before invasive mechanical ventilation is associated with adverse clinical outcome. Thus, it is unknown if delaying invasive ventilation worsens clinical outcome. In this study, the research question is whether early compared to late endotracheal intubation improves clinical outcome (duration of invasive mechanical ventilation, mortality)? The aim is to identify the optimal S/F ratio and respiratory rate thresholds for initiating intubation to either improve survival or reduce the duration of invasive ventilation without compromising survival. This is achieved by comparing 25 dynamic treatment regimes defined by combinations of S/F thresholds (<any, 250, 200, 150, 100) and respiratory rate thresholds (>any, 16, 20, 25, 30). Thresholds indicating less severe illness (e.g., S/F < 250 and RR > 16) are considered 'early intubation,' while thresholds indicating more severe illness (e.g., S/F < 100 and RR > 30) are considered 'late intubation'.

Two sensitivity analyses will be conducted:

  • Restricting to patients without hypercapnia (pCO2 < 45), excluding those with missing pCO2 values or pCO2 > 45.
  • Including only patients with non-missing Glasgow Coma Scale (GCS) values and adjusting for GCS as a confounder.

Additionally, seven subgroup analyses will be conducted:

  • Patients diagnosed with COVID-19
  • Patients with a history of COPD
  • Patients with a history of CHF
  • Patients with BMI ≤ 30
  • Patients with BMI > 30
  • Patients on high-flow nasal oxygen (HFNO) at time zero
  • Patients on non-invasive ventilation (NIV) at time zero

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Hospitalized (inpatient or ICU)
  • 18 years or older
  • Hypoxemic respiratory failure: S/F<250
  • Not yet intubated

Exclusion criteria

  • Do not intubate order
  • Presence of tracheostomy

Treatment and study plan

Endotracheal Intubation

Procedure

endotracheal intubation for invasive mechanical ventilation

Primary outcomes

  1. 28-day RMTL of mortality

    Time frame: 28 days

    Mortality restricted mean time lost (RMTL) over the 28-day period (area under the cumulative incidence function curve)

  2. 28-day mortality risk

    Time frame: 28 days

    Mortality risk at day 28

Study contacts

Contact information is provided by the study sponsor or research team.

Carmen A.T. Reep, MSc

CONTACT

[email protected]

+31628164764

Evert-Jan Wils, PhD, MD

CONTACT

[email protected]

Sponsors and collaborators

Lead sponsor

Erasmus Medical Center

Other

Registry information

Official study title

Effects of Early vs. Delayed Invasive Mechanical Ventilation: A Target Trial Emulation

Acronym: NORMO2

Important dates

Study start
2018
Primary completion
2025
Study completion
2025
First posted
Jan 3, 2025
Registry last updated
Jan 3, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.